SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10803	Companies
233757	Keywords
162417	Articles
124804	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 06/04/2026 at 10:07, 2 months 1 day ago

Press Release: Sanofi launches 2026 global employee stock purchase plan
Sanofi launches Action 2026 global employee stock purchase plan involving 75,000 employees in 52 countries. Employees offered discounted shares with free matching shares and limited purchase amount. Eligibility conditions and holding periods apply

Shares Sanofi Global Employee Stock Purchase Plan Action 2026
BRIEF

published on 05/28/2026 at 07:05, 2 months 8 days ago

Sanofi's venglustat under priority review by the FDA for type 3 Gaucher disease

FDA Sanofi Venglustat Gaucher's Disease Priority Examination
BRIEF

published on 05/28/2026 at 07:05, 2 months 8 days ago

Sanofi's Venglustat Granted Priority Review for Type 3 Gaucher Disease

Sanofi FDA Review Venglustat Gaucher Disease Neurological Treatment
BRIEF

published on 05/28/2026 at 07:05, 2 months 8 days ago

Le venglustat de Sanofi obtient un examen prioritaire pour la maladie de Gaucher de type 3

Sanofi Examen De La FDA Venglustat Maladie De Gaucher Traitement Neurologique
BRIEF

published on 05/28/2026 at 07:05, 2 months 8 days ago

Le venglustat de Sanofi en examen prioritaire par la FDA pour la maladie de Gaucher de type 3

FDA Sanofi Examen Prioritaire Venglustat Maladie De Gaucher
PRESS RELEASE

published on 05/28/2026 at 07:00, 2 months 8 days ago

Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi's venglustat granted priority review by FDA for treating type 3 Gaucher disease. Potential first US therapy for neurological manifestations with target action date on November 25, 2026

FDA Sanofi Venglustat Gaucher Disease Neurological Manifestations
PRESS RELEASE

published on 05/28/2026 at 07:00, 2 months 8 days ago

Communiqué de presse : Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3
Sanofi's venglustat granted priority review by FDA for type 3 Gaucher disease treatment. Potential first US therapy for neurological manifestations. Action date set for Nov 25, 2026

FDA Sanofi Venglustat Type 3 Gaucher Disease Priority Review
BRIEF

published on 05/19/2026 at 18:42, 2 months 16 days ago

Sanofi Reports Voting Rights and Share Information for April 2026

Voting Rights French Commercial Code Shares Sanofi April 2026
BRIEF

published on 05/19/2026 at 18:42, 2 months 16 days ago

Sanofi publie les informations relatives aux droits de vote et aux actions pour avril 2026

Actions Droit De Vote Sanofi Code De Commerce Français Avril 2026
PRESS RELEASE

published on 05/19/2026 at 18:37, 2 months 16 days ago

Sanofi: Information concerning the total number of voting rights and shares - April 2026
Sanofi discloses total voting rights and shares information as per French Commercial Code and French stock market authority regulations

French Commercial Code Total Voting Rights Shares Information Sanofi Stock Market Authority

Accesswire

Published on 08/05/2026 at 14:00, 47 minutes ago

Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders
Published on 08/05/2026 at 13:30, 1 hour 17 minutes ago

Nextech3D.ai Signs Strategic Partnership with F2B Services to Drive AI Software Adoption, Expand LED Display Opportunities and Accelerate Event Technology Growth
Published on 08/05/2026 at 13:30, 1 hour 17 minutes ago

International Battery Metals Announces First Quarter Fiscal 2027 Financial Results Conference Call and Webcast
Published on 08/05/2026 at 13:00, 1 hour 47 minutes ago

Global Education Communities Corp. Announces Executive Appointments and Leadership Updates
Published on 08/05/2026 at 13:00, 1 hour 47 minutes ago

Galway Metals Reports Broad Gold Intercepts from Southwest Deposit, Including 2.6 g/t Over 48.0 Metres

View all ACCESSWIRE

EQS Group

Published on 08/05/2026 at 14:35, 12 minutes ago

Utility Global Names Robert Lane Chief Financial Officer to Drive Commercialization at Scale
Published on 08/05/2026 at 14:30, 16 minutes ago

Edison issues report on Templeton Emerging Markets Investment Trust (TEM)
Published on 08/05/2026 at 14:00, 46 minutes ago

EUROPLASMA: Information relative au nombre total de droits de vote et d’actions composant le capital au 31 juillet 2026
Published on 08/05/2026 at 13:23, 1 hour 24 minutes ago

Application for Block Listing
Published on 08/05/2026 at 13:00, 1 hour 47 minutes ago

Nebius appoints Lindsey Irvine as Chief Marketing Officer

Les Echos

Published on 08/05/2026 at 14:16, 30 minutes ago

LNA Santé : Répartition de capital et des droits de vote attachés aux actions au 31/07/2026
Published on 08/05/2026 at 13:52, 54 minutes ago

Disclosure of Share Capital and Voting Rights as of July 31, 2026
Published on 08/05/2026 at 13:52, 54 minutes ago

Déclaration du nombre d’actions et droits de vote au 31 juillet 2026
Published on 08/05/2026 at 13:33, 1 hour 14 minutes ago

Actualisation du document d'enregistrement universel 2025
Published on 08/04/2026 at 19:16, 19 hours 31 minutes ago

Covivio - 2026 Half-year financial report

View all LES ECHOS COMFI WIRE